Now, obviously those are going to be other investigators, not myself, who are going to present that data. Now we’re going to follow those patients for longer period of time. That’s probably the longest kind of median duration of follow up that we have in those patients. But that durability is measured at a year to 18 months or longer.
Albeit it is a morbid procedure and associated with non-trivial mortality rate. And that durable CR… and I think we have to remember that durability in metastatic disease is very different and should be looked at through a different lens than durability in localized disease, which is highly curable with a surgical procedure like radical cystectomy. And essentially demonstrates that about one in five patients will have durable CRs in the bladder with the systemic immunotherapy in patients who have BCG-unresponsive CIS. Our very first podcast was about that data and, the maturity that we published earlier this year in Lancet Oncology is kind of what’s in the public domain. What’s happened to that program? What updates have we had? Has the data matured well, like fine wine? Or has it been more like one of my trials, which seems to get worse and worse and has ratio drops? The first podcast we did together was with you and Seth Lerner and pembro had just been approved in non-muscle invasive urothelial cancer and BCG refractory disease in the CIS population. So firstly, I wanted to talk about non-muscle invasive urothelial cancer. It’ll become apparent how it will unfold for those who are listening. I see why, because we’ve got three or four things we’re going to talk about. You’re unemployed currently, is that accurate? And I’m in transition now awaiting a new job, which I’ll start. But as of today, formerly, the GU director there and also formerly the CTO medical director there. Tom and Brian, my name is Arjun Balar, a medical oncologist and still an associate Professor of Medicine at NYU Langone Health’s Perlmutter Cancer Center. Arjun, do you want to introduce yourself really quickly? Arjun Balar discusses bladder cancer and his recent move to industry.
0 kommentar(er)
